At 7, I Had 6 Months to Live. One Call Changed Everything
Chase Malackowski was diagnosed with Ewing's Sarcoma at eight years old. After trialing a "single patient Investigational New ...
Targeted Oncology11h
FDA Clears Novel Cancer Immunotherapy R-5780 for Early-Stage Trial
R-5780, an oral immuno-oncology drug designed to activate gut-regulated immune pathways, will now be evaluated in a phase 1 ...
Taiwan News3h
Celltrion unveils strategic vision for advancing its innovative drug pipeline at the 43rd Annual J.P. Morgan Healthcare Conference
INCHEON, South Korea, Jan. 15, 2025 /PRNewswire/ -- Celltrion, Inc. (068270.KS), a leading global biopharmaceutical company, today announced its innovative drug development strategy in the rigorous ...
VisiRose Announces $3 Million Seed Financing Round to Advance Ocular Therapeutics
VisiRose Inc. (”VisiRose” or the “Company”), a privately-held, clinical-stage biotechnology company developing novel ocular ...
Targeted Oncology1d
FDA Grants Clearance for Phase 1b/2 Trial of SNB-101 in SCLC
The investigational new drug application for the nanoparticle drug SNB-101 has been cleared for small cell lung cancer ...
manilatimes1d
Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma
Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) and AbbVie Inc. (NYSE: ABBV) today announced ...
Crain's Chicago Business1d
AbbVie keeps adding cancer treatments with $1B licensing deal for new drug
In its latest attempt to bulk up its cancer drug portfolio, AbbVie has signed a new licensing agreement with China-based Simcere Zaiming to develop a treatment for myeloma, a type of blood cancer, in ...
Solid Biosciences Outpaces Competitors In Duchenne Gene Therapy Development (CORRECTED)
Solid Biosciences advances gene therapies for muscular and cardiac diseases, gaining FDA clearance for SGT-212 and targeting ...
AbbVie and Simcere Zaiming Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma
AbbVie (NYSE: ABBV) and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) today announced an option to license agreement to develop SIM0500, an investigational new drug ...